Leerink Partnrs Issues Negative Forecast for Humana Earnings

Humana Inc. (NYSE:HUM) – Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for shares of Humana in a research note issued on Wednesday, October 30th. Leerink Partnrs analyst W. Mayo now expects that the insurance provider will post earnings of ($2.16) per share for the quarter, down from their prior estimate of ($1.57). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Humana’s current full-year earnings is $16.15 per share. Leerink Partnrs also issued estimates for Humana’s Q1 2025 earnings at $6.91 EPS, Q2 2025 earnings at $7.08 EPS, Q3 2025 earnings at $3.68 EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at $16.86 EPS, FY2026 earnings at $16.09 EPS and FY2027 earnings at $28.36 EPS.

HUM has been the subject of several other reports. JPMorgan Chase & Co. upped their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. UBS Group reduced their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday. Barclays lifted their price target on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday. One research analyst has rated the stock with a sell rating, nineteen have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $312.95.

Humana Price Performance

Shares of NYSE HUM opened at $260.66 on Monday. Humana has a twelve month low of $213.31 and a twelve month high of $527.18. The firm has a market capitalization of $31.39 billion, a P/E ratio of 23.09, a P/E/G ratio of 2.02 and a beta of 0.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $293.25 and its two-hundred day simple moving average is $333.56.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. raised its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the period. Creative Financial Designs Inc. ADV increased its holdings in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana in the 3rd quarter worth $29,000. Hantz Financial Services Inc. bought a new stake in shares of Humana in the second quarter worth about $35,000. Finally, Family Firm Inc. bought a new stake in shares of Humana in the second quarter worth about $37,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.